- First, incorporate the overall development of the peptide innovative drug industry into the major development strategy of the national pharmaceutical industry, especially the special strategy of the “14th Five-Year” development plan.
- Second, encourage enterprises to accelerate technological innovation.
- Third, formulate relevant talent policies.
“From the perspective of the global innovative drug industry, after nearly a century of development in Western countries, small molecule drugs have made discovery of new drugs more and more difficult;
large molecule drugs have huge R&D and production costs, resulting in extremely high costs for patients to use drugs, which cannot benefit the people.
Peptide drugs, which are between small molecules and large molecules, are increasingly favored by the market.”
During the two sessions this year, Tang Yue, deputy to the National People’s Congress and chairman of Chutian Technology, suggested vigorously supporting the development of innovative peptide drugs.
Driven by the huge market demand, and with the promotion of government policies, it is completely feasible for my country’s new peptide drug industry to achieve overtaking on a curve.
Polypeptides are a class of compounds connected by amino acids through chemical bonds. They are widely used in the fields of medicine, cosmetics, and nutritional products, especially in the field of medicine.
For example, insulin and oxytocin are polypeptide drugs. Compared with small molecule drugs, peptide drugs have significant characteristics such as high activity and low toxicity, and are increasingly favored by the market.
However, due to the complex structure and easy degradation of peptide molecules, the development of new drugs also faces great technical challenges.
The research and development of new peptide drugs is difficult, and the domestic peptide pharmaceutical industry chain is incomplete and lacks industrial cluster effect;
the synthesis equipment and separation and purification equipment for preparing peptides mainly rely on imports. Therefore, Tang Yue gave four suggestions in the proposal:
First, incorporate the overall development of the peptide innovative drug industry into the major development strategy of the national pharmaceutical industry, especially the special strategy of the “14th Five-Year” development plan.
Provide support from the national strategic level, comprehensively use financial, taxation, capital market and other support policies, start from solving basic stuck neck projects, and focus on support to achieve a phased breakthrough in peptide drug innovation.
The development of innovative peptide drugs is of great significance to the improvement of the quality of the development of my country’s biomedical industry.
Accelerating the creation of a number of high-tech new peptide drug R&D companies and peptide synthesis and purification equipment manufacturers with hard power in the R&D field is the basis for achieving peptide drug innovation.
Second, encourage enterprises to accelerate technological innovation.
Select a number of companies (projects) with new peptide drug R&D and innovation capabilities to be included in the “National Major New Drug Development” National Science and Technology Special Project, and give priority to promoting the use of domestic peptide synthesis equipment, purification equipment and domestic fillers, so that peptide research can truly enter localization.
It is recommended that these outstanding small and medium-sized enterprises should be included in major special support in a timely manner at the national level, so as to connect resources for the development of enterprises and promote enterprises with innovative capabilities to become bigger and stronger.
Third, formulate relevant talent policies.
Vigorously introduce professional leading talents around the development of peptide innovative drugs, and solve the talent bottleneck of peptide industry development by formulating peptide development industrial policies, talent incentive policies, talent cultivation policies, and encouraging and advocating the large-scale use of domestic key equipment.
Concentrate efforts to build a number of peptide biomedical industrial parks with demonstration and driving functions.
Vigorously promote domestic research equipment and production-oriented industrial equipment.
The research and development of new peptide drugs has a long industrial chain. If it is too fragmented and developed separately, it is not conducive to the overall resource allocation of the industry.
It is recommended to build one or several core enterprises with technological innovation strength around the key technologies and special equipment that are urgently needed in the industry to build a characteristic peptide pharmaceutical industrial park, form an industrial cluster effect, and gather various resources such as upstream and downstream industries, talents, and funds. Promote a virtuous circle of enterprise and industrial development.